Theme: An Insight into Advanced Research and Diagnostic Approaches in Alzheimer’s Disease and Dementia

Dementia 2016

Dementia 2016

            On behalf of the Conference Organizing Committee, it is with great pleasure that we welcome you to the official website of 5th International Conference on Alzheimer’s disease and Dementia during September 29-October 01, 2016 at London, UK.

Dementia is a general term that describes a group of symptoms such as loss of memory, judgment, language, complex motor skills, and other intellectual function caused by the permanent damage or death of the brain's nerve cells, or neurons. Dementia, including Alzheimer’s disease, is one of the biggest global public health challenges facing our generation.

Track 1: Causes and Prevention of Alzheimer’s

Alzheimer's is caused by brain cell death. It is a neurological disorder in which the death of brain cells causes memory loss and cognitive decline. The total size of the brain shrinks in Alzheimer's, nerve cells and connections in the tissue progressively reduced, which cannot be seen or tested in the living brain affected by Alzheimer's disease, post-mortem/autopsy will always show tiny inclusions in the nerve tissues, called as plaques and tangles. Plaques are found between the dying cells in the brain - from the build-up of a protein called beta-amyloid (amyloid plaques). The tangles exist in the brain neurons, from a disintegration of second protein, called tau.

Worldwide, with Dementia or Related disorders nearly 44 million people have suffered in 2015,past results shown 35.66 million population  lived with dementia  worldwide in year 2010, with numbers expected to nearly double each twenty years, to 65.7 million in 2030 and 115.4 million in 2050. In 2010, fifty eight per cent of all population with dementia lived in countries with lower or moderate incomes, with this proportion anticipated to rise to 63% till 2030 and 71% by 2050. This condition is anticipated to double by 2030 and quite triple by 2050 to 115 million.

In this track we can discuss on Neurological changes in brain, Amyloid protein, Genetic associations and susceptibility genes, Role of Apo lipoprotein E, Brain trauma, Metabolic syndrome and Alzheimer’s disease, Protein misfolding, aggregation and toxicity, Disease-causing mutations, Epidemiology and prevalence, Histone modification, DNA methylation, Alzheimer’s disease prevention.

 

Related Dementia Conferences | Alzheimers conferences | Dementia Meetings | Neuroscience Conferences

6th World Congress on Neurology and Neurological disorders, September 28-30, 2016 Toronto, Canada; 2nd International Conference on Sleep Disorders and Medicine, November 28-30, 2016 Atlanta, USA, 2nd International Conference on Central Nervous System Disorders and Therapeutics, December 5-7 2016, Dubai, UAE; 2nd International Conference on Parkinson’s Disease and Movement Disorders November 28-30, 2016 Atlanta, USA; International Conference on Neurorehabilitation, July 21-22, 2016 Brisbane, Australia; 7thGlobal Neurologists Annual Meeting on Neurology and Neuro Surgery, August 22-24, 2016 Vienna, Austria; 1st Middle Eastern Conference for Stereotactic and Functional Neurosurgery 2016, Dubai; InternationalConference on Deep Brain Stimulation (DBS), Germany. 6th Annual Traumatic Brain Injury ConferenceWashington, United States. 21st International Conference on Brain Tumor Research and Therapy, 17thInternational conference on pediatric neurooncology , Accelerated Cure Project for Multiple Sclerosis and Acid Maltase Deficiency AssociationAcoustic Neuroma Association and ADA Disability and Business Technical Assistance ProgramAicardi Syndrome Foundation and Alliance for Aging Research, ALS Association and ALS Therapy Development InstituteAlternating Hemiplegia of Childhood Foundation and Alzheimer’s Drug Discovery Foundation.

 

Track 2: Managing Dementia

Dementia is the term used to describe the symptoms of a number of conditions that affecting the brain. The commonly seen condition is Alzheimer’s, and other includes Parkinson's disease. Symptoms seen at early stages are personality changes, withdrawal, memory loss, confusion and apathy. Early diagnosis helps with providing early treatment, support and planning. Medications might help with some symptoms of dementia, but no permanent cure.

Majority of people with dementia are above age 65, the condition is not normal for all older people. The occurrence of dementia gets high with age, but it’s not given that an older person will develop it. While only 1-in-4 people with Alzheimer’s disease or Dementia has been diagnosed. Few more things we need to know about vascular dementia, Dementia with lewy bodies, Fronto-temporal dementia, Rarer causes of dementia, Creutzfeldt-Jakob disease, HIV-related cognitive impairment, Mild cognitive impairment.

 

Related Dementia Conferences | Alzheimers conferences | Dementia Meetings | Neuroscience Conferences

2nd International Conference on Sleep Disorders and Medicine, November 28-30, 2016 Atlanta, USA, 2nd International Conference on Central Nervous System Disorders and Therapeutics, December 5-7 2016, Dubai, UAE; 6th World Congress on Neurology and Neurological disorders, September 28-30, 2016 Toronto, Canada;  2nd International Conference on Parkinson’s Disease and Movement Disorders November 28-30, 2016 Atlanta, USA; International Conference on Neurorehabilitation, July 21-22, 2016 Brisbane, Australia; 7th GlobalNeurologists Annual Meeting on Neurology and Neuro Surgery, August 22-24, 2016 Vienna, Austria; 1st Middle Eastern Conference for Stereotactic and Functional Neurosurgery 2016, Dubai; International Conference on Deep Brain Stimulation (DBS), Germany. 6th Annual Traumatic Brain Injury Conference Washington, United States. 21st International Conference on Brain Tumor Research and Therapy, 17th International conference on pediatric neurooncology , Accelerated Cure Project for Multiple Sclerosis and Acid Maltase Deficiency AssociationAcoustic Neuroma Association and ADA Disability and Business Technical Assistance Program,Aicardi Syndrome Foundation and Alliance for Aging Research, ALS Association and ALS Therapy Development InstituteAlternating Hemiplegia of Childhood Foundation and Alzheimer’s Drug Discovery Foundation.

 

Track 3: Alzheimer’s disease Diagnosis and Symptoms

Alzheimer’s disease is that the commonest type of dementia, it is a serious brain disorder and it impacts daily living through memory loss and cognitive changes. Although not all memory loss indicates Alzheimer’s disease, one in ten people over 65 years of age, and over half of those over 85 have Alzheimer’s disease. Currently, 26 million people worldwide have this dementia, and over 15 million Americans will be affected by the year 2050.

There is no single test that can show whether a person has Alzheimer's. While physicians can almost always determine if a person has dementia, it may be difficult to determine the exact cause. Diagnosing Alzheimer'srequires careful medical evaluation, including medical history, mental status testing, physical and neurological exam, blood tests and brain imaging.

Symptoms of Alzheimer’s disease usually develop slowly and gradually worsen over time, progressing from mild forgetfulness to widespread brain impairment. Chemical and structural changes in the brain slowly destroy the ability to create, remember, learn, reason, and relate to others. As critical cells die, drastic personality loss occurs and body systems fail.

This session includes  Biomarkers, Novel approaches in biomarkers, Living with Alzheimer’s disease, Patients psychological changes, Neuropathology and Neuropsychology, Early detection possibilities, Different diagnosis procedures, New methods in diagnosis, Normal brain aging.

 

Related Dementia Conferences | Alzheimers conferences | Dementia Meetings | Neuroscience Conferences

International Conference on Neurorehabilitation, July 21-22, 2016 Brisbane, Australia; 7th Global Neurologists Annual Meeting on Neurology and Neuro Surgery, August 22-24, 2016 Vienna, Austria; 2nd InternationalConference on Parkinson’s Disease and Movement Disorders November 28-30, 2016 Atlanta, USA; 6th WorldCongress on Neurology and Neurological disorders, September 28-30, 2016 Toronto, Canada; 2nd InternationalConference on Sleep Disorders and Medicine, November 28-30, 2016 Atlanta, USA,  1st Middle Eastern Conference for Stereotactic and Functional Neurosurgery 2016, Dubai; International Conference on Deep Brain Stimulation (DBS), Germany. 2nd International Conference on Central Nervous System Disorders and Therapeutics, December 5-7 2016, Dubai, UAE;    6th Annual Traumatic Brain Injury ConferenceWashington, United States. 21st International Conference on Brain Tumor Research and Therapy, 17thInternational conference on pediatric neurooncology , Accelerated Cure Project for Multiple Sclerosis and Acid Maltase Deficiency AssociationAcoustic Neuroma Association and ADA Disability and Business Technical Assistance ProgramAicardi Syndrome Foundation and Alliance for Aging Research, ALS Association and ALS Therapy Development InstituteAlternating Hemiplegia of Childhood Foundation and Alzheimer’s Drug Discovery Foundation.

 

Track 4: Alzheimer’s disease Imaging

Scientists look at the brain’s grey matter when investigating about Alzheimer’s disease. A fresh study, found that degenerating white matter in the brain could be an early indicator of disease. A study was published in Radiology which concludes that white matter plays an important role in how the disease strikes and progresses. Abnormal deposits of proteins that form amyloid plaques and tau tangles all over the brain in Alzheimer’s disease. It can also be characterized by shrinkage of brain tissues due to neurons loss.

This session includes Amyloid and Tau imaging, Imaging animal models, Imaging and genetics, New methods in imaging, Structural and functional MRI, Positron emission tomography, MR spectroscopy, EEG and brain mapping, SPECT imaging, Imaging correlates of clinical, cognitive and biomarker variables.

 

Related Dementia Conferences | Alzheimers conferences | Dementia Meetings | Neuroscience Conferences

10th World Congress on Neurology and Therapeutics, March 27-29, 2017 Madrid, Spain; 2nd InternationalConference on Brain Disorders and Therapeutics October 27-29, 2016 Chicago, USA; 6th World Congress on Neurology and Neurological disorders, September 28-30, 2016 Toronto, Canada; 7th Global Neurologists Annual Meeting on Neurology and Neuro Surgery, August 22-24, 2016 Vienna, Austria; 8th European Neurology Congress, September 21-23, 2016, Amsterdam, Netherlands; 31st International Epilepsy congress, Istanbul; Mechanisms of Epilepsy and Neuronal Synchronization, Spain; 2nd International Workshop on High Frequency Oscillations in Epilepsy Germany; 12th European Congress on Epileptology, Czech Republic; Traumatic Brain Injury: Clinical, Pathological and Translational Mechanisms, USA.  Angelman Syndrome Foundation and Angioma AllianceAntiepileptic Drug Pregnancy Registry and Aphasia Hope FoundationBrain Aneurysm Foundation and Brain Injury Association of America, Inc.Brain Injury Resource Center and Brain Trauma FoundationCerebral Palsy Foundation and CHADD - Children and Adults with Attention-Deficit/Hyperactivity Disorder.

 

Track 5: Alzheimer’s disease Pathophysiology and Disease Mechanisms

Alzheimer’s disease is a progressive dementia with loss of neurons and the presence of two main microscopic neuropathological hallmarks: extracellular amyloid plaques and intracellular neurofibrillary tangles. Early onset AD, a rare familial form, is caused due to mutation of one out of three genes: (amyloid precursor protein), (presenilin 2) or (presenilin 1).  Sporadic form occurs usually after age of 65 and accounts for most cases; it most likely results from a combination of genetic and influence of environment. Confirmed risk factors for sporadic AD are age and the presence of the E4 allele of (Apo lipoprotein E). Amyloid plaques comprise mainly of the neurotoxic peptide amyloid (Aβ, Abeta), cleaved sequentially from a larger precursor protein (APP) by two enzymes: β-secretase (also called BACE1) and γ-secretase (comprising four proteins, presenilin is one of them). If APP is first cleaved by the enzyme α-secretase rather than β-secretase then Aβ is not formed. Neurofibrillary tangles comprise mainly of the protein tau which binds with microtubules, which facilitating the neuronal transport system. Tau uncoupling from microtubules and aggregation into tangles inhibits transport and results in disassembly of microtubule. Phosphorylation of tau might have an important role in this. Selective vulnerability of neuronal systems such as the cholinergic, serotonergic, and noradrenergic and glutamatergic systems form the basis of current rational pharmacological treatment.

This session includes Aging, Prions and Alzheimer’s disease, Cellular signaling and cell to cell transmission, Oxidative damage and mitochondrial dysfunction, Autoimmunity in Alzheimer’s, Blood-brain barrier and transport, Neurogenesis and stem cells and Cell death.

 

Related Dementia Conferences | Alzheimers conferences | Dementia Meetings | Neuroscience Conferences

7th Global Neurologists Annual Meeting on Neurology and Neuro Surgery, August 22-24, 2016 Vienna, Austria; 9th Global Neuroscience Conference November 07-09, 2016 Melbourne, Australia; 2nd International Conference on Sleep Disorders and Medicine, November 28- 30, 2016, Chicago, USA; 2nd International Conference on Parkinson’s Disease & Movement Disorders November 28-30, 2016 Atlanta, USA; International Conference on Bipolar DisordersSchizophrenia & Mental Disorders, October 26-27, 2016 Chicago, USA; American Epilepsy Society Annual Meeting, USA; 53rd Annual Congress of the German League Against Epilepsy, Germany; 12th European Congress on Epileptology, Czech Republic; 18th Annual Meeting of Infantile Seizure Society, Japan; 13th Eilat Conference on New Antiepileptic Drugs (EILAT XIII), Spain. Charcot-Marie-Tooth Association and Charlie Foundation for Ketogenic TherapiesChildren's Hemiplegia and Stroke Assocn and Children's Tumor FoundationChristopher and Dana Reeve Foundation and Citizens United for Research in EpilepsyComa/Traumatic Brain Injury Recovery Association and Compassionate FriendsDravet Syndrome Foundation and Dysautonomia Foundation

 

Track 6: Amyloid Protein in Alzheimer’s and Dementia

The amyloid plaques and neurofibrillary tangles formation are thought to contribute to the degradation of the neurons (nerve cells) in the brain and the subsequent symptoms of Alzheimer's disease.

Amyloid Plaques: One of the hallmarks of Alzheimer's disease is the accumulation of amyloid plaques between nerve cells (neurons) in brain. Amyloid generally indicates protein fragments that the body produces normally. Beta amyloid is a protein fragment from an amyloid precursor protein (APP). In a healthy brain, these protein fragments are broke down and get eliminated. In Alzheimer’s, the fragments gets accumulated to form hard &insoluble plaques.

Neurofibrillary Tangles: Neurofibrillary tangles are insoluble twisted fibers found inside the brain's cells, consisting primarily of a protein called tau, which forms structure called a microtubule. Transport of nutrients and other important substances from one part of the nerve cell to another done by help of microtubule. InAlzheimer's disease, the tau protein is abnormal and results in collapse of the microtubule structures.

This session includes Amyloid Protein and Alzheimer’s Disease, Amyloid beta metabolism in Alzheimer’s, Brain accumulation of toxic amyloid beta, Amyloid Plaques and Neurofibrillary Tangles, Amyloid Neuroimaging andbiomarkers, Amyloidosis and Neurodegeneration, The amyloid hypothesis and potential treatments, Amyloid beta deposition, cognition and brain volume.

 

Related Dementia Conferences | Alzheimers conferences | Dementia Meetings | Neuroscience Conferences

6th World Congress on Neurology and Neurological disorders, September 28-30, 2016 Toronto, Canada; 2nd International Conference on Central Nervous System Disorders and Therapeutics, December 5-7 2016, Dubai, UAE; 2nd International Conference on Parkinson’s Disease & Movement Disorders November 28-30, 2016 Atlanta, USA; International Conference on Neurorehabilitation, July 21-22, 2016 Brisbane, Australia; 7thGlobal Neurologists Annual Meeting on Neurology and Neuro Surgery, August 22-24, 2016 Vienna, Austria; 1st Middle Eastern Conference for Stereotactic and Functional Neurosurgery 2016, Dubai; InternationalConference on Deep Brain Stimulation (DBS), Germany; 13th Eilat Conference on New Antiepileptic Drugs (EILAT XIII), Spain; Global Symposium on Ketogenic Therapies, Canada; Brazilian Epilepsy Congress, Brazil. World Health OrganizationAccelerated Cure Project for Multiple Sclerosis and Acid Maltase Deficiency Association,  Alternating Hemiplegia of Childhood Foundation and Alzheimer’s Drug Discovery Foundation,American Association on Health and Disability and American Autoimmune Related Diseases Association,American RSD Hope Organization and American Sleep Apnea Association.

 

Track 7: Geriatrics Dementia and Cognitive Disorder

Geriatrics or geriatric medication may be a specialty that focuses on health care of older people. It aims to push health by preventing and treating diseases and disabilities in older adults. there's no set age at that patients is also underneath the care of a specialist or geriatric MD, a MD United Nations agency makes a specialty of the care of older people. Rather, this call is set by the individual patient’s needs, and therefore the availableness of a specialist. It’s vital to notice the distinction between gerontology, the care of aged people, and geriatrics, that is that the study of the aging method itself.

Cognitive disorders square measure a class of mental state disorders that primarily have an effect on learning, memory, perception, and drawback determination, and embody blackout, dementia, and delirium. Whereas anxiety disorders, mood disorders, and psychotic disorders can even have an effect on psychological feature and memory functions, the DSM-IV-TR doesn't contemplate these psychological feature disorders, because loss of cognitive function is not the primary (causal) symptom. Causes vary between the various sorts of disorders however most include damage to the memory parts of the brain. Treatments rely on however the disorder is caused. Medication and therapies square measure the foremost common treatments but, for a few sorts of disorders like amnesia, treatments will suppress the symptoms however there is presently no cure.

This session includes Neurodegenerative diseases, Geriatric emergency medicine, Geriatric diagnostics,Geriatric neurology, Geriatric oncology, Geriatric psychiatry or psychogeriatric, Geriatric pharmacotherapy, Alcohol addiction and mental health, Nutritional deficiency, Preventions: Mental activity and healthy lifestyle.

 

Related Dementia Conferences | Alzheimers conferences | Dementia Meetings | Neuroscience Conferences

International Conference on Autism September 15-16, 2016 Phoenix, Arizona, USA; 9th Global Neuroscience Conference November 07-09, 2016 Melbourne, Australia; 5th International Conference on Addiction Researchand Therapy October 06-08, 2016 Florida, USA; 5th International Conference on Alzheimer’s Disease &Dementia September 29-October 01, 2016 London, UK; 2nd International Conference on Sleep Disorders and Medicine November 28-30, 2016 Atlanta, USA; British Pediatric Neurology Association Conference 2016, UK; American Professional Society of ADHD 2016, USA; Brazilian Epilepsy Congress, Brazil; 12th EuropeanCongress on Epileptology, Czech Republic; 18th Annual Meeting of Infantile Seizure Society, Japan. Brain Aneurysm Foundation and Brain Injury Association of America, Inc., Angelman Syndrome Foundation and Angioma AllianceAntiepileptic Drug Pregnancy Registry and Aphasia Hope FoundationBrain Injury Resource Center and Brain Trauma FoundationCerebral Palsy Foundation and CHADD - Children and Adults with Attention-Deficit/Hyperactivity Disorder.

 

Track 8: Care Practice and Awareness

Persons with dementia have multiple psychological feature deficits that include each memory impairment, that affects the flexibility to find out new info or recall information previously learned, and one or additional of the subsequent symptoms-aphasia, apraxia, agnosia, or executive dysfunction-such that the psychological feature deficits negatively have an effect on social or activity functioning with a big decline in previous talents. Additionally, persons with dementia typically suffer from comorbid conditions that additional complicate care and impede best outcomes. Therefore, developing caregiving methods people with dementia is urgent, given this increasing prevalence and therefore the associated burden that dementia places not only on the individuals, however on the caregivers, relations, and therefore the resources of the health care system. Conventional views bearing on geriatric nursing typically paint an image of the care as being slow paced certain and less demanding than acute care. However, care of the aged, and particularly those with dementia, is usually complicated, unpredictable, and unstable.

This session includes Education and training of medical professionals, Care and quality of life, Person centered care, Cognitive training, Support and training for informal and professional careers, Putting scientific knowledge into practice, Non-pharmacological Interventions, Functional foods, Art, music and life style.

 

Related Dementia Conferences | Alzheimers conferences | Dementia Meetings | Neuroscience Conferences

10th World Congress on Neurology and Therapeutics, March 27-29, 2017 Madrid, Spain; 2nd InternationalConference on Brain Disorders and Therapeutics, October 27-29, 2016 Chicago, USA; 5th InternationalConference on Alzheimer’s Disease & Dementia September 29-October 01, 2016 London, UK; 2nd Annual Experts Meeting on DepressionAnxiety and Stress Management, November 7-8, 2016, Valencia, Spain; 4th International Conference on Vascular Dementia June 30 - July 02, 2016 Valencia, Spain; 2nd Dravet Syndrome Conference, USA; 14th Canadian Angelman Syndrome Society conference, Canada; 4thInternational Family and Professional Conference on Lennox-Gastaut Syndrome, USA; 2nd International Workshop on High Frequency Oscillations in Epilepsy, Germany; Mechanisms of Epilepsy and Neuronal Synchronization , Spain.Charcot-Marie-Tooth Association and Charlie Foundation for Ketogenic TherapiesChildren's Hemiplegia and Stroke Assocn and Children's Tumor FoundationChristopher and Dana Reeve Foundation and Citizens United for Research in EpilepsyComa/Traumatic Brain Injury Recovery Association and Compassionate Friends,Dravet Syndrome Foundation and Dysautonomia Foundation

 

Track 9: Therapeutic Targets and Mechanisms for Treatment

Alzheimer's disease is a progressive neurodegenerative disease that is characterized histopathologically by the presence of plaques, mainly composed of Abeta amyloid and the tangles, mainly composed of hyperphosphorylated tau. To date, there is no treatment that can reverse the disease, and all the current therapeutics is directed to cope with the symptoms of the disease. Here we describe the efforts dedicated to attack the plaques and, in more detail, the process of neurofibrillary degeneration, linked to the presence of the hyperphosphorylated microtubule associated protein tau. We have identified the different putative targets for therapeutics and the current knowledge on them.

Treatment for Alzheimer's disease is entering a new and exciting phase, with several new drugs beginningclinical trials. Many of these new therapies are based on our best current understanding of the pathogenesis of Alzheimer's disease, and are designed to try to either slow or halt the progression of the disease. There are several different theories underlying the current efforts, and these are briefly reviewed. Therapies directed against some aspect of beta-amyloid formation, against neurofibrillary tangle formation and against the inflammatory response are all considered, as are the problems associated with each area. It is as yet unclear which, if any, of these approaches will be successful, but the high level of activity in each of these three fields provides some hope that an effective treatment for Alzheimer's disease is on the horizon.

This session includes Abeta, truncated and pGlu-Abeta, Immunotherapy, Neurotransmitter-based targets, Anti-inflammatory targets, Nanotechnology, Anti-oxidants, Neurotrophic factors, Protein aggregation, Deep brain stimulation, Misfolding and chaperones, Gene therapy, Drug-delivery systems.

 

Related Dementia Conferences | Alzheimers conferences | Dementia Meetings | Neuroscience Conferences

2nd International Conference on Sleep Disorders and Medicine, November 28-30, 2016 Atlanta, USA, 2nd International Conference on Central Nervous System Disorders and Therapeutics, December 5-7 2016, Dubai, UAE; 6th World Congress on Neurology and Neurological disorders, September 28-30, 2016 Toronto, Canada;  2nd International Conference on Parkinson’s Disease and Movement Disorders November 28-30, 2016 Atlanta, USA; International Conference on Neurorehabilitation, July 21-22, 2016 Brisbane, Australia; 7th GlobalNeurologists Annual Meeting on Neurology and Neuro Surgery, August 22-24, 2016 Vienna, Austria; 1st Middle Eastern Conference for Stereotactic and Functional Neurosurgery 2016, Dubai; International Conference on Deep Brain Stimulation (DBS), Germany. 6th Annual Traumatic Brain Injury Conference Washington, United States. 21st International Conference on Brain Tumor Research and Therapy, 17th International conference on pediatric neurooncology , Accelerated Cure Project for Multiple Sclerosis and Acid Maltase Deficiency AssociationAcoustic Neuroma Association and ADA Disability and Business Technical Assistance Program,Aicardi Syndrome Foundation and Alliance for Aging Research, ALS Association and ALS Therapy Development InstituteAlternating Hemiplegia of Childhood Foundation and Alzheimer’s Drug Discovery Foundation.

 

Track 10: Animal Models and Translational Medicine

Animal models for Alzheimer’s disease it is important to think about the human phenotype and what is being modeled in terms of the animal phenotype. The moderator, Bradley Hyman, professor of neurology at Harvard Medical School, said that animal models of Alzheimer’s disease, based on the genetics of the disease and the closely related frontotemporal dementia, replicate at least some of the pathology. Researchers have been successful at modeling very specific aspects of Alzheimer’s disease in the mouse (e.g., plaques, tangles). Although these are incomplete models of the human disease, they have been well received in the field as potentially relevant models for use in drug discovery.

Patients with Alzheimer’s disease will display both amyloidopathy and tauopathy; however, scientists often focus, in a reductionist way, on one or the other in an animal model. A participant added that even though the anatomy in the mouse is different than the human, mutant tau mice are relatively good models in that they recapitulate tau-dependent neurodegeneration. This has led a number of companies to focus on antibodies that block tau-dependent neurodegeneration in these mouse models.

This session includes Transgenic models, Pharmacological and lesion models, Natural and seminatural models, Primate models, Zebra fish models, Animal models of human cognitive aging, Development of new animal models, Genetics of translational models, Protein-protein interactions, Ethical issues with animal models.

 

Related Dementia Conferences | Alzheimers conferences | Dementia Meetings | Neuroscience Conferences

6th World Congress on Neurology and Neurological disorders, September 28-30, 2016 Toronto, Canada; 2nd International Conference on Sleep Disorders and Medicine, November 28-30, 2016 Atlanta, USA, 2nd International Conference on Central Nervous System Disorders and Therapeutics, December 5-7 2016, Dubai, UAE; 2nd International Conference on Parkinson’s Disease and Movement Disorders November 28-30, 2016 Atlanta, USA; International Conference on Neurorehabilitation, July 21-22, 2016 Brisbane, Australia; 7thGlobal Neurologists Annual Meeting on Neurology and Neuro Surgery, August 22-24, 2016 Vienna, Austria; 1st Middle Eastern Conference for Stereotactic and Functional Neurosurgery 2016, Dubai; InternationalConference on Deep Brain Stimulation (DBS), Germany. 6th Annual Traumatic Brain Injury ConferenceWashington, United States. 21st International Conference on Brain Tumor Research and Therapy, 17thInternational conference on pediatric neurooncology , Accelerated Cure Project for Multiple Sclerosis and Acid Maltase Deficiency AssociationAcoustic Neuroma Association and ADA Disability and Business Technical Assistance ProgramAicardi Syndrome Foundation and Alliance for Aging Research, ALS Association and ALS Therapy Development InstituteAlternating Hemiplegia of Childhood Foundation and Alzheimer’s Drug Discovery Foundation.

 

OMICS International Conferences invites all the participants from all over the world to attend ‘5th International Conference on Alzheimer’s Disease & Dementia’ during September 29-October 01, 2016 at London, UK  which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions.

Dementia, including Alzheimer’s disease, is one of the biggest global public health challenges facing our generation. Worldwide, at least 44 million people are living with dementia this number is expected to double by 2030 and more than triple by 2050 to 115 million. Much of the increase will be in developing countries like Western Europe and North America. Already 62% of people with dementia live in developing countries. Today, over 35 million people worldwide currently live with the condition. This number is expected to double by 2030 and more than triple by 2050 to 115 million. No treatments available to slow or stop the brain damage caused by Alzheimer’s disease, several medications can temporarily help improve the symptoms of dementia for some people. In two decades, it is estimated that 1.4 million Canadians will have dementia, costing the economy almost $300 billion per year. Globally, dementia cost $600 billion a year.

Why to attend???

Dementia 2016 will provide an opportunity for all stakeholders working on Alzheimer’s disease and Dementia to talk about their work. Dementia 2016 will congregate renowned speakers, principal investigators, experts, neurologist’s and Dementia researchers from both academia and health care industry will join together to discuss their views and research. The conference will be comprised of sessions by world class experts in the field of neurology. In Dementia 2016, international symposiums, B2B meetings, international workshops will also be organized to discuss the specific topics in the field of Dementia and Neurology.

Target Audience:

  • Neurologists and Directors
  • Physicians
  • Neuroscientists
  • Specialists
  • researchers
  • Health care professionals
  • Professors
  • Industrial Experts
  • Neurosurgeons
  • Psychiatrist
  • Nutritional Scientists
  • Lecturers and Students from Academia in the study of Dementia
  • Students from Academia in the research of Neurology

OMICS International organizes conference series all around the world in 2016, here we welcome you to the 5th International Conference on Alzheimer’s disease and Dementia September during 29-October 01, 2016 at London, UK.

Dementia 2016 mainly focusing on Alzheimer’s disease, Dementia, Neurological changes in brain, Alzheimer’s disease Imaging, Disease Mechanisms, Geriatrics and Cognitive Disorder, Pathophysiology, Brain trauma, Care practice and Awareness, Current Research in Dementia and Alzheimer’s Disease.

Importance & Scope:

Dementia is a general term that describes a group of symptoms-such as loss of memory, judgment, language, complex motor skills, and other intellectual function-caused by the permanent damage or death of the brain's nerve cells, or neurons.

Dementia, including Alzheimer’s disease, is one of the biggest global public health challenges facing our generation.

Globally, results of a recent meta-analysis suggest that 44 million people lived with dementia worldwide in 2010, with numbers expected to almost double every 20 years, to 65.7 million in 2030 and 115.4 million in 2050. In 2010, 58 percent of all people with dementia lived in countries with low or middle incomes, with this proportion anticipated to rise to 63 percent in 2030 and 71 percent in 2050.This number is expected to double by 2030 and more than triple by 2050 to 115 million.

In the United States alone, experts estimate that as many as five million people age 65 and older suffer from Alzheimer’s disease.  

 

Why London?

The United Kingdom of Great Britain and Northern Ireland, commonly known as the United Kingdom (United Kingdom) or Britain is a sovereign state located off the north-western coast of continental Europe. The country includes the island of Great Britain (a term sometimes loosely applied to the whole state), the north-eastern part of the island of Ireland, and many smaller islands.

The total area of the United Kingdom is approximately 243,610 square kilometres (94,060 sq mi). The country occupies the major part of the British Isles archipelago and includes the island of Great Britain, the north-eastern one-sixth of the island of Ireland and some smaller surrounding islands. The United Kingdom has a temperate climate, with plentiful rainfall all year round.

England and Scotland was leading Centre of the Scientific Revolution from the 17th century and the United Kingdom led the Industrial Revolution from the 18th century, and has continued to produce scientists and engineers credited with important advances. Scientific research and development remains important in British universities, with many establishing science parks to facilitate production and co-operation with industry. Between 2004 and 2008 the United Kingdom produced 7% of the world’s scientific research papers and had an 8% share of scientific citations, the third and second highest in the world.

 

Conference Highlights:

Causes and Prevention of Alzheimer’s

Managing Dementia

Alzheimer’s disease Diagnosis and Symptoms

Alzheimer’s disease Imaging

Alzheimer’s disease Pathophysiology and Disease Mechanisms

Amyloid Protein in Alzheimer’s and Dementia

Geriatrics and Cognitive Disorder

Care Practice and Awareness

Therapeutic Targets and Mechanisms for Treatment

Animal Models and Translational Medicine

 

Why to attend???

Meet Your Target Scientists, Professors Achieved Eminence in Their Field of Study with members from around the world focused on learning about Dementia and Alzheimer’s, this is your single best opportunity to reach the largest assemblage of participants from all over the world. Conduct demonstrations, distribute information, meet with current and potential scientific discoveries, make a splash with a new product line, and receive name recognition at this 3-day event. World-renowned speakers, the most recent findings and the newest updates in Alzheimer’s disease and Dementia fields are hallmarks of this conference.

 

Be Part of it!

This conference focusing on all the major aspects in the fields of Dementia, Alzheimer’s as well as Aging.

It would be beneficial for all the students who ever willing to enter into corporate worlds targeting to the respective fields

 

This Meeting strategic astuteness is to be an event for bringing together Scientists, Physicians, International mix of leading Universities, Alzheimer’s and Dementia Institutions to transform the practices to control and cure these Diseases.

 

Members Associated with Dementia

Alzheimer's Research UK currently funds 150 research projects across the UK and has committed nearly £40million to dementia research.

Their research will focus on improving the quality of life of those already living with Alzheimer’s disease and other forms of dementia.

The Alzheimer's Association funds independent investigators worldwide, they have awarded over $335 million to more than 2,250 projects.

 

Associations around the United Kingdom:

Alzheimer's Society

Dementia UK - Alzheimer's Society

Alzheimer's & Dementia Help UK

Dementia UK

Lewy Body Society

Dementia Friends

Dementia Action Alliance

Association for Dementia Studies

The Frontotemporal Dementia Support Group

Lewy Body Dementia Association

Association for Frontotemporal Degeneration

 

Alzheimer Association & Societies around the Globe

Alzheimer's Australia

Albanian Alzheimer Society

Association de Lucha contra el Mal de Alzheimer

Foundation Alzheimer Aruba (FAA)

Alzheimer's Australia

Alzheimer Austria

Alzheimer Support Group

Alzheimer Society of Bangladesh

Barbados Alzheimer's Association Inc.

Alzheimer’s and Dementia Association of The Cayman Islands

Ligue National Alzheimer Liga

Alzheimer's Family Support Group

Association Bolivian de Alzheimer y Otras Dementias

FEBRAZ - Federico Brasilia de Associaçãoes de Alzheimer

Corporation Alzheimer Chile

Alzheimer's disease Chinese

Alzheimer Association & Societies in Canada

 

Target Audience:

Neurologists and Directors, Physicians, Neuroscientists, Specialists, researchers, health care professionals, Professors, Lecturers and Students from Academia in the study of Dementia.

 

Universities in and around London which are working in the field of Alzheimer’s:

University College London

King college London –UK

Kingston University

University of West London

Brunel University London

The University of Buckingham

Queen Mary, University of London

University of Worcester

UWS - University of the West Scotland

Bristol University

Imperial College London

 

Market Value and Growth on Dementia:

Research conducted by the Alzheimer's Society, shows that there will be 850,000 people living with dementia in the UK by 2015. This will cost the UK £26 billion a year.

Two-thirds (£17.4 billion) of the cost of dementia is paid by people with dementia and their families, either in unpaid care (£11.6 billion) or in paying for private social care. This is in contrast to other conditions, such as heart disease and cancer, where the NHS provides care that is free at the point of use.

 

Products manufactured by the industries:

Three drugs are available to treat symptoms in people with Mild to moderate Alzheimer’s disease

Aricept™ produced by Pfizer Canada Inc.,

Exelon™ produced by Novartis Pharma Canada Inc.

Reminyl™ produced by Janssen Ortho Inc.

Two drugs for Moderate to advanced Alzheimer’s disease

Ebixa®

Aricept™

 

References:

http://www.alzheimers.org.uk/dementiauk

https://en.wikipedia.org/wiki/Alzheimer's_Research_UK

http://www.alzheimersresearchuk.org/

http://www.alz.org/uk/dementia-alzheimers-uk.asp

http://www.alzheimersresearchuk.org/about-dementia/facts-stats/

http://www.alz.org/research/funding/alzheimers_our_commitment.asp

https://www.ucl.ac.uk/dementia

http://www.city.ac.uk/courses/cpd/evidence-based-dementia-care

http://www.kcl.ac.uk/ioppn/depts/oldage/research/bdr.aspx

Dementia 2015

In the presence of inter professional researchers and practitioners involved in the development of high quality education in all aspects of Alzheimer’s disease and Dementia, OMICS 3rd International Conference on Alzheimer’s Disease & Dementia was held during August 31-September 02, 2015 in Toronto, Canada.

OMICS International played host to a diverse panel of key members of the Neurology community from research lab, industry, academia and financial investment practices, discussing the future of Alzheimer’s and Dementia. This event was really aimed for examining where the real Alzheimer’s disease and Dementia specialties are going in the future and purpose of the event was to provide an opportunity for cross fertilization of ideas and development of ideas, in the field of Neurology.

Focusing on Alzheimer’s disease, Dementia, Neurological changes in brain, Alzheimer’s disease Imaging, Disease Mechanisms, Geriatrics and Cognitive Disorder, Pathophysiology, Brain trauma, Care practice and Awareness, Current Research in Dementia and Alzheimer’s Disease as well, the three days of discussions enabled professionals to gain an insight into the current innovations and opened up networking opportunities.

Dementia-2015 Organizing Committee would like to thank the Moderator of the conference Catherine Braxton, Generations Senior Care Consulting, USA, who contributed a lot for the smooth functioning of this event.


We are also thank full to all the speakers who made this event a grand success, our special thanks to 

  • Barbara C Fisher, United Psychological Services, USA
  • Guosong liu, Neurocentria, Inc., USA
  • Tohru Hasegawa, Saga Woman Junior College, Japan
  • Claude M Wischik, TauRx Therapeutics, UK
  • Zhicheng Xiao, Monash University, Australia
  • Helen Chenery, Bond University, Australia
  • Eef Hogervorst, Loughborough University, UK
  • Linda Levine Madori, St. Thomas Aquinas College, USA
  • Jens Wiltfang, Georg August University Gottingen, Germany

The highlights of the meeting were the eponymous lectures, delivered by Barbara C Fisher from United Psychological Services, USA, Claude M Wischik from TauRx Therapeutics, UK, Guosong liu from Neurocentria, Inc., USA, Zhicheng Xiao from Monash University, Australia, Tohru Hasegawa fromSaga Woman Junior College, Japan, Helen Chenery from Bond University, Australia.

The entire above mentioned keynote speakers gave their energetic and fruitful contributions at 3rd International Conference on Alzheimer’s Disease & Dementia.  The session chairs/Co chairs have proved their position and contributed a lot for the smooth functioning of the event.

All accepted abstracts have been indexed in the OMICS Group Journals as a special issue. OMICS Group felicitated all the Organizing Committee Members who enthusiastically participated in the conference and made this meeting a huge success.

With the huge response from scientific fraternity, industries, renowned personalities and Editorial Board Members of OMICS Group across the world, we would like to proudly announce “5th International Conference on Alzheimer’s Disease & Dementia” during September 29-October 01, 2016 in London, UK

We wish to pioneer a way to another outstanding event in the UK.

 

Past Reports  Proceedings  Gallery  

Dementia 2014

 

The 2nd International Conference on Alzheimer’s Disease and Dementia was organized by OMICS Group Inc., during September 23-25, 2014 at Valencia Convention Centre, Spain. With the support and contribution of the Organizing Committee Members, we successfully hosted the event at the conference venue.

Active participation and generous response was received from the Organizing Committee Members, Editorial Board Members of OMICS Group Journals, scientists, researchers, as well as experts from Alzheimer’s Disease and Dementia, Non-government organizations, and students from diverse groups who made this conference as one of the most successful and productive events in 2014 from OMICS Group.

The conference was marked with the attendance of young and brilliant researchers, business delegates and talented student communities representing more than 35 countries, who have driven this event into the path of success.   

The conference was initiated with a warm welcome note and the Book Launch from Honorable guests and the Keynote forum lead by Dr. Sudhakar Yakkanti, Honorable President, OMICS Group Inc. The proceedings went through interactive sessions and panel discussions headed by Dr. Lydia Gimenez Llort, Autonomous University of Barcelona, Spain and Dr. Melinda Martin-Khan, the University of Queensland, Australia honorable Moderator for the conference.

The conference proceedings were carried out through various Scientific-sessions and plenary lectures, of which the following Speakers were highlighted as Keynote speakers:

Eric G. TangalosMayo Clinic, USA

Sanjay AsthanaUniversity of Wisconsin, USA

Howard RowleyUniversity of Wisconsin, USA

Toru ItakuraWakayama Medical University, Japan

Alan PalmerCerebroscience Ltd, UK

Barbara C. FisherUnited Psychological Services, USA

Nigel HooperUniversity of Manchester, UK

Federico LicastroUniversity of Bologna, Italy

OMICS Group has taken the privilege of felicitating Dementia-2014 Organizing Committee, Editorial Board Members and Keynote Speakers who supported for the success of this event. OMICS Group, on behalf of the conference exhibitors congratulates the Best Poster awardees for their outstanding performance in the field of Alzheimer’s Disease and appreciates all the participants who put their efforts in poster presentations and sincerely wishes them success in future endeavours.   

The esteemed guests, Keynote speakers, well-known researchers and delegates shared their innovative research and vast experience through their fabulous presentations at the podium of grand Dementia-2014. We are glad to inform that all accepted abstracts for the conference have been indexed in OMICS Group Journal of Alzheimer’s Disease and Parkinsonism as a special issue. Basing on the conference theme, "Advanced Diagnostic & Therapeutic Approaches Towards Dementia” speakers recommended organizing the conference in the field of Alzheimer’s Disease and Dementia also in the next year.

We are also obliged to various delegate experts, company representatives and other eminent personalities who supported the conference by facilitating active discussion forums. We sincerely thank the Organizing Committee Members

George Perry, University of Texas at San Antonio, USA

Eric G. TangalosMayo Clinic, USA

Sanjay Asthana, University of Wisconsin, USA

Piotr Lewczuk, Universitatsklinikum Erlangen, Germany

Fangyu Peng, University of Texas Southwestern Medical Center, USA

Lydia Gimenez Llort, Autonomous University of Barcelona, Spain

Eef Hogervorst, Loughborough University, UK

Jerzy Leszek, Medical University in Wroclaw, Poland

Robert J. Buchanan, University of Texas, USA, for their gracious presence, support, and assistance towards the success of Addiction Therapy-2014. With the unique feedback from the conference, OMICS Group would like to announce the commencement of the "3rdInternational Conference on Alzheimer’s Disease and Dementia " to be held during August 31-September 02, 2014 at Toronto, Canada

 


Past Reports  Gallery  

PsychoAAD-2013

The International Conference on Psychology, Autism and Alzheimer’s Disease, organized by OMICS Group International was successfully held at Hilton San Antonio Airport, TX, USA during September 30-October 01, 2013. The conference was organized with the theme “Global Perspectives and Current Trends in Psychology"


The conference was marked with the presence of renowned scientists, talented young researchers, students and business delegates representing more than 20 different countries ultimately driving the event into the path of success.

OMICS Group International would like to convey a warm gratitude to all the Honorable guests of PsychoAAD-2013. The highlights of the conference were its educative and effectual keynote lectures by:

Joseph M. RifkindNational Institute of Aging, USA

Jaykumar RajdasStanford University, USA

H. Craig HellerStanford University, USA

George PerryUniversity of Texas at San Antonio, USA

Ronald J. KillianyBoston University, USA

Mitchell ClionskyClionsky Neuro Systems, USA

Kalyani GopalAmerican Psychological Association, USA

OMICS Group is grateful to Dr. Andrew V. SchallyNobel Prize in Medicine 1977, for his time and dedication as Honourable Organizing Committee Member, for his exceptional support towards PsychoAAD 2013.

OMICS Group also took the privilege of felicitating PsychoAAD-2013 Organizing CommitteeEditorial Board Members of Journal of Psychology & Psychotherapy,Journal of Alzheimer's Disease & Parkinsonism and Autism- Open AccessKeynote Speakers,  Chair and Co-Chairs whose support led the conference into the path of excellence.

Our special gratitude to our Collaborators Autism Community Network & Lebanese Psychological Association and Media Partners APPAC, Greece;  Med tube, USA;  ABP,Brazil; International Early Psychosis Association, Australia; Alzheimer’s Europe and Institute for forensic Criminology, Italy

After the immense and grand response received for the International Conference on Psychology, Autism and Alzheimer’s Disease, OMICS Group International proudly announces the commencement of its "2nd International Conference on Alzheimer’s Disease & Dementia" to be held during September 23-25, 2014 at Valencia, Spain.


Past Reports  Gallery  

sponsor

Want to Differentiate your company from your competitors and broaden your competitive edge?

Use our global platform of 3000+ Global Events

  • 25 Million+ Visitors to our Global website (conferenceseries.com)
  • 20000+ Unique Visitors per conference
  • 60000+ Page views per conference

For customized sponsorship opportunities at our conferences, or to place an ad on our websites, contact at sponsors@conferenceseries.com or call at: +1-650-268-9744

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date September 29-October 01, 2016
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity
Poster Opportunity Available

Media Partners

Conferenceseries Destinations


Mail us at

Drop us an email for Program enquiry.
dementia@neuroconferences.com
Sponsors / Exhibiting / Advertising.
dementia@neuroconferences.com
General Queries.
dementia@conferenceseries.net

View Proceedings of Previous Conferences

Dementia 2015 Conference Proceedings
Dementia 2014 Conference Proceedings
PsychoAAD 2013 Conference Proceedings
Neurology 2012 Conference Proceedings
Authorization Policy

By registering for the conference you grant permission to Conferenceseries LLC to photograph, film or record and use your name, likeness, image, voice and comments and to publish, reproduce, exhibit, distribute, broadcast, edit and/or digitize the resulting images and materials in publications, advertising materials, or in any other form worldwide without compensation. Taking of photographs and/or videotaping during any session is prohibited. Contact us for any queries.